Evidence map›Paper›PMID 37237781›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Penicillin-Susceptible

Samuel Raemy, Carlo Casanova, Rossella Baldan, Erin Barreto, Aaron J Tande, Andrea Endimiani, Stephen L Leib, Urs Fischer, Parham Sendi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Samuel RaemyInstitute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.
Carlo CasanovaInstitute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.ORCID 0000-0002-7888-6329
Rossella BaldanInstitute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.
Erin BarretoDepartment of Pharmacy, Mayo Clinic, Rochester, MN 55902, USA.ORCID 0000-0002-0996-1487
Aaron J TandeDivision of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Andrea EndimianiInstitute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.
Stephen L LeibInstitute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.
Urs FischerDepartment of Neurology, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-0521-4051
Parham SendiInstitute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.ORCID 0000-0002-7347-6312
University of Bern · CHMayo Clinic · USMayo Clinic in Florida · US

Funding

Beta-lactam individualization for critically ill patientsK23AI143882 · NIAID · MAYO CLINIC ROCHESTER · PI BARRETO, ERIN FRAZEE · 2020 to 2024
$986k
NIAID NIH HHS K23 AI143882
6 · The paper itself

Abstract

The recommended empiric ceftriaxone dosing regimen for acute bacterial meningitis in adults is 2 g every 12 h. After penicillin-susceptible

Indexed as

ceftriaxonecerebrospinal fluidmeningitispenicillinStreptococcus pneumoniae

Identifiers

PMID37237781
PMCPMC10215215
OpenAlexW4378515158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.